Pulmonx Co. (NASDAQ:LUNG) Director Sells $130,400.00 in Stock

Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III sold 20,000 shares of Pulmonx stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $6.52, for a total transaction of $130,400.00. Following the transaction, the director now directly owns 1,091,974 shares in the company, valued at $7,119,670.48. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Pulmonx Price Performance

LUNG stock opened at $6.13 on Thursday. The stock has a 50-day moving average price of $7.31 and a two-hundred day moving average price of $7.34. Pulmonx Co. has a 1 year low of $5.46 and a 1 year high of $14.84. The stock has a market cap of $237.94 million, a PE ratio of -3.98 and a beta of 0.64. The company has a current ratio of 8.97, a quick ratio of 7.92 and a debt-to-equity ratio of 0.37.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, July 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02. Pulmonx had a negative return on equity of 50.79% and a negative net margin of 75.56%. The business had revenue of $20.78 million for the quarter, compared to analyst estimates of $20.23 million. Equities analysts forecast that Pulmonx Co. will post -1.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Wells Fargo & Company reduced their price target on shares of Pulmonx from $14.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Canaccord Genuity Group boosted their target price on Pulmonx from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $14.83.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC grew its holdings in shares of Pulmonx by 261.2% in the 2nd quarter. Squarepoint Ops LLC now owns 144,409 shares of the company’s stock valued at $916,000 after acquiring an additional 104,432 shares in the last quarter. Sei Investments Co. increased its position in shares of Pulmonx by 2.5% during the 1st quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock worth $673,000 after purchasing an additional 1,800 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Pulmonx by 7.0% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,059,018 shares of the company’s stock worth $6,714,000 after purchasing an additional 69,595 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Pulmonx in the 2nd quarter valued at approximately $222,000. Finally, Renaissance Technologies LLC grew its stake in shares of Pulmonx by 13.1% in the second quarter. Renaissance Technologies LLC now owns 301,410 shares of the company’s stock valued at $1,911,000 after buying an additional 34,800 shares in the last quarter. Institutional investors own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.